Source / U.S. research ethics framework

The Belmont Report

The Belmont Report is a short U.S. federal commission statement on the ethics of biomedical and behavioral research involving people. The Commission transmitted it in 1978, and the Department of Health, Education, and Welfare (DHEW) published it for public comment on 18 April 1979.

Its lasting contribution was not a new statute or a complete rulebook, but a common language—respect for persons, beneficence, and justice—for reasoning about consent, risk and benefit, and the selection of research participants.

Reading the report

Three principles organize practical questions without settling them automatically.

The report first distinguishes research from professional practice, then states three principles, then connects those principles to three applications. It repeatedly acknowledges that hard cases remain disputable; the principles are an analytical framework, not a hierarchy or an algorithm. The period phrase “human subjects” is retained when identifying the report and its legal setting; “participants” is generally preferred here for people who take part in research.

Research is defined by its purpose

Belmont describes practice as intervention intended to enhance the wellbeing of a particular patient or client, and research as activity designed to test a hypothesis or contribute to “generalizable knowledge.” A new or untested treatment is not automatically research, but an activity containing a research element should receive independent review. This distinction helped decide which activities entered the oversight system, while leaving difficult boundary cases that later scholars continue to debate.

Respect joins autonomy to protection

People capable of deliberation should be treated as autonomous agents; those whose autonomy is diminished are entitled to protection. The application is informed consent, analysed as information, comprehension, and voluntariness—not merely a signed form. Belmont also exposes an internal tension: protection can guard people facing dependency or coercion, yet excessive protection can deny them a meaningful choice to participate.

Beneficence makes welfare an obligation

The report uses “beneficence” more strongly than ordinary kindness: researchers should avoid harm, maximise possible benefits, and minimise possible harms. Its risk–benefit assessment considers the probability and magnitude of physical, psychological, legal, social, and economic harms. Investigators must examine design and alternatives; reviewers must ask whether remaining risks are justified; prospective participants need the assessment to decide whether to enrol.

Justice concerns burdens and benefits

Justice asks who is recruited, who carries risk, and who can benefit from the resulting knowledge or treatment. Belmont recalls poor hospital-ward patients, concentration-camp prisoners, and the U.S. Public Health Service syphilis study at Tuskegee to show that convenient or politically weak groups had borne research burdens. It therefore rejects recruitment based simply on availability, compromised position, or manipulability and also asks whether publicly supported advances will reach more than those able to pay.

The official text published by the Office for Human Research Protections supports this structure and wording. Its examples reflect a U.S. document written in the 1970s; they should not be mistaken for a universal origin story of research ethics or for current clinical guidance.

Chronology and setting

Belmont entered an oversight system already under construction.

1947–1971: codes, criticism, and prior review. The Nuremberg Code (1947) and World Medical Association's Declaration of Helsinki (1964, revised in 1975) preceded Belmont. In the United States, Henry K. Beecher's 1966 article “Ethics and Clinical Research” documented ethically troubling studies in prominent institutions. That year the Public Health Service required prior institutional review for the extramural research it funded; DHEW extended review across the department in 1971. Belmont therefore consolidated and interpreted an evolving system rather than inventing ethical review.

1972–1974: exposure, hearings, rules, and legislation. Jean Heller's July 1972 Associated Press reporting brought national attention to the Public Health Service's decades-long syphilis study involving Black men in and around Tuskegee, Alabama. The project had deceived participants and withheld effective treatment. Congressional hearings in 1973 considered that study alongside broader abuses in human experimentation. DHEW formally issued 45 CFR part 46 on 30 May 1974. This sequence is reconstructed in Zachary Schrag's archival history. President Richard Nixon then signed the National Research Act, Public Law 93-348, on 12 July. The Act required institutional review boards for covered grant and contract applicants and created an eleven-member National Commission to identify principles and develop guidelines.

1974–1978: a commission, not a solitary author. The Commission included physicians, behavioral scientists, lawyers, ethicists, and Dorothy Height, president of the National Council of Negro Women. It produced specific work on research involving fetuses, prisoners, children, people then described in law with the now-obsolete phrase “the institutionalized mentally infirm,” and on IRBs. At a four-day retreat in February 1976, commissioners reduced several candidate duties to three principles. Staff philosopher Tom Beauchamp prepared successive drafts; commissioners, staff, and consultants reviewed and compressed them over the next two years. The Commission's DHEW booklet records its members, staff, consultants, and chairman Kenneth Ryan's transmission letter.

1978–1979: transmission and public notice. The Commission approved the wording in 1978 and transmitted the report to the DHEW secretary on 30 September. It asked DHEW to adopt the whole statement as departmental policy but proposed no specific administrative action in this report. On 18 April 1979 DHEW reproduced it in the Federal Register, 44 FR 23192–23197, as a notice of report for public comment. Calling Belmont simply a “1979 law” therefore misstates both its date and its legal status.

1981–1991: regulation and wider adoption. HHS and the Food and Drug Administration revised and aligned their existing human-participant rules in 1981; in 1991, fifteen federal departments and agencies adopted the common policy now called the Common Rule. The sequence matters: later regulation drew on the Commission's work, but statutes, departmental rules, and topic-specific commission recommendations—not Belmont alone—built the oversight system.

Influence, disagreement, and limits

A durable framework acquired a larger reputation than its makers expected.

Its regulatory influence is real but contested

HHS describes Belmont as foundational background for the 1981 revisions and a continuing ethical basis for IRB work. Historians qualify a simple line of descent: Zachary Schrag shows that review requirements and disputes over behavioral and social research preceded the report, while Hiroyuki Nagai, Eisuke Nakazawa, and Akira Akabayashi argue that Belmont cannot be credited with the basic portions of the rules made uniform in 1981. The safest conclusion is influence through language and interpretation, alongside law, earlier regulation, and the Commission's more specific reports.

Consent can overshadow justice

Belmont does not formally rank its principles. Yet in 2004 oral-history interviews, staff writer Tom Beauchamp called justice a “distant third,” and commissioner Patricia King described it as the “forgotten principle.” Those are retrospective judgments recorded twenty-five years later, not neutral evidence of every 1970s deliberation. They nevertheless identify a durable problem: procedural attention to individual consent can leave institutional racism, poverty, unequal access, and the social distribution of research priorities insufficiently examined.

Protection can also produce exclusion

Grouping people as “vulnerable” may prompt necessary safeguards against coercion and exploitation. It can also exclude children, pregnant people, prisoners, disabled people, or others from evidence and potential benefits. Belmont itself recognises the dilemma in its discussion of prisoners, but it offers no general formula for deciding when protection becomes paternalism.

New research exposes gaps in the original frame

Phoebe Friesen and colleagues point to blurred boundaries among research and practice, commercial complexity, and group harms; Lainie Friedman Ross and colleagues develop a framework for harms to community members and communities as wholes. These critiques do not make Belmont useless. They show why community authority, transparency, structural justice, and context-specific rules may need to supplement its participant-centred framework.

The debate should not be flattened into praise or dismissal. Belmont's brevity made it portable across professions, while the same generality leaves its principles open to competing interpretations. Ethical review requires specification, evidence, institutional accountability, and participant or community involvement; citing the three words is not itself protection.

Across the collection

Continue from the Belmont Report

History of medical ethics

Connect research protections to professional duties, patient rights, public health, coercion, and resource justice.

History of clinical trials

Follow controls, randomisation, consent, regulation, registration, participant advocacy, and changing standards of evidence.

The Nuremberg Code

Compare Belmont's general principles with the ten requirements written into the 1947 Doctors' Trial judgment.